Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News and Analysis
  • Published:

2017 FDA drug approvals

Nature Reviews Drug Discovery volume 17, pages 81–85 (2018)Cite this article

Subjects

A Corrigendum to this article was published on 01 February 2018

This article has been updated

The FDA approved 46 new drugs last year, the highest total in more than two decades.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Novel FDA approvals since 1993.
Figure 2: 2017's potential blockbuster approvals.
Figure 3: CDER approval trends over time.
Figure 4: CDER approvals by therapeutic area in 2017.

Change history

  • 01 February 2018

    Semaglutide is the sixth GLP1 agonist to receive FDA approval, not the fifth as originally noted. This correction has been made in the print and online versions.

Authors
  1. Asher Mullard
    View author publications

    You can also search for this author in PubMed Google Scholar

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mullard, A. 2017 FDA drug approvals. Nat Rev Drug Discov 17, 81–85 (2018). https://doi.org/10.1038/nrd.2018.4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd.2018.4

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research